Your browser doesn't support javascript.
loading
Mapping SARS-CoV-2 antigenic relationships and serological responses.
Wilks, Samuel H; Mühlemann, Barbara; Shen, Xiaoying; Türeli, Sina; LeGresley, Eric B; Netzl, Antonia; Caniza, Miguela A; Chacaltana-Huarcaya, Jesus N; Corman, Victor M; Daniell, Xiaoju; Datto, Michael B; Dawood, Fatimah S; Denny, Thomas N; Drosten, Christian; Fouchier, Ron A M; Garcia, Patricia J; Halfmann, Peter J; Jassem, Agatha; Jeworowski, Lara M; Jones, Terry C; Kawaoka, Yoshihiro; Krammer, Florian; McDanal, Charlene; Pajon, Rolando; Simon, Viviana; Stockwell, Melissa S; Tang, Haili; van Bakel, Harm; Veguilla, Vic; Webby, Richard; Montefiori, David C; Smith, Derek J.
Afiliación
  • Wilks SH; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Mühlemann B; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Shen X; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Türeli S; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
  • LeGresley EB; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Netzl A; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Caniza MA; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Chacaltana-Huarcaya JN; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Corman VM; Department of Global Pediatric Medicine, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Daniell X; Hospital Nacional Daniel A. Carrión, Callao, Bellavista, Peru.
  • Datto MB; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Dawood FS; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Denny TN; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
  • Drosten C; Department of Pathology, Duke University School of Medicine, Durham, NC, USA.
  • Fouchier RAM; Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Garcia PJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
  • Halfmann PJ; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Jassem A; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Jeworowski LM; Erasmus Medical Center, Rotterdam, Netherlands.
  • Jones TC; School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Kawaoka Y; Influenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Krammer F; BC Centre for Disease Control, Vancouver, British Columbia, Canada.
  • McDanal C; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Pajon R; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Simon V; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Stockwell MS; German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany.
  • Tang H; Influenza Research Institute, Department of Pathobiological Science, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • van Bakel H; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Veguilla V; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Webby R; Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Tokyo, Japan.
  • Montefiori DC; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Smith DJ; Department of Pathology, Cellular and Molecular Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Science ; 382(6666): eadj0070, 2023 10 06.
Article en En | MEDLINE | ID: mdl-37797027
ABSTRACT
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multiple variants escaping preexisting immunity emerged, causing reinfections of previously exposed individuals. Here, we used antigenic cartography to analyze patterns of cross-reactivity among 21 variants and 15 groups of human sera obtained after primary infection with 10 different variants or after messenger RNA (mRNA)-1273 or mRNA-1273.351 vaccination. We found antigenic differences among pre-Omicron variants caused by substitutions at spike-protein positions 417, 452, 484, and 501. Quantifying changes in response breadth over time and with additional vaccine doses, our results show the largest increase between 4 weeks and >3 months after a second dose. We found changes in immunodominance of different spike regions, depending on the variant an individual was first exposed to, with implications for variant risk assessment and vaccine-strain selection.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 / COVID-19 / Vacunas de ARNm / Antígenos Virales Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Science Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 / COVID-19 / Vacunas de ARNm / Antígenos Virales Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Science Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido